Citadel Advisors
CTOR

Citadel Advisors’s Citius Oncology CTOR Stock Holding History

Citadel Advisors’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.9K Buy
+90,586
New +$72.2K ﹤0.01% 13046
2025
Q4 		– Sell
-17,661
Closed -$35.9K – 14410
2025
Q3 		$35.9K Buy
+17,661
New +$38.3K ﹤0.01% 12335
2025
Q1 		– Sell
-22,699
Closed -$26.1K – 15813
2024
Q4 		$26.1K Buy
+22,699
New +$25.5K ﹤0.01% 12994

Other funds holding CTOR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Citadel Advisors's CTOR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Citius Oncology (CTOR) in Q2 2026: 90,586 shares worth $58.9K. The stake represents ﹤0.01% of the portfolio and ranks #13046 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CTOR as recently as Q3 2025.

Citadel Advisors first reported a position in CTOR in Q4 2024 and has held it in 3 quarters since. 19 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

  • Citadel Advisors held 90,586 shares of Citius Oncology worth $58.9K as of Q2 2026.
  • Citius Oncology was a new Citadel Advisors position in Q2 2026.
  • Citius Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13046 holding.
  • Citadel Advisors first reported a position in Citius Oncology in Q4 2024 and has held it in 3 quarters since.
  • 19 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.